BMY—Breyanzi shows phase-3 statsig-superior EFS compared to SoC (high-dose chemo followed by stem-cell transplant) in second-line, large B-cell lymphoma:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.